1 research outputs found
Unveiling the hidden struggles: Exploring the profound impact of advanced stage cutaneous Tâcell lymphoma on quality of life
Abstract Erythrodermic mycosis fungoides and SĂ©zary syndrome are chronic, relapsingâremitting diseases that greatly impacts patients' quality of life (QoL). Mogamulizumabâkpkc (Mogamulizumab) is a novel therapeutic agent for cutaneous Tâcell lymphomas with a notable impact on progressionâfree survival. Qualitative assessment methods allow a broader exploration and greater insight in individual patient experience than quantitative studies. However, there is limited data on the impact of mogamulizumab on healthârelated QoL. To investigate the impact of erythrodermic cutaneous Tâcell lymphoma (EâCTCL) on QoL and the effect of mogamulizumab on the QoL. Semiâstructured interview were conducted with seven patients with EâCTCL that were receiving mogamulizumab treatment. Five major themes arose: Diagnosis and the diagnostic delay and uncertainty experienced by participants; Physical functioning due to the high symptom burden; Psychological and social functioning considering the significant impact on daily life; Treatment and the effect of mogamulizumab; and Support by family, friends and health professionals. Mogamulizumab therapy resulted in a significant decrease of symptoms. The small sample size should also be taken into account although data saturation was reached. This study gives a broad insight into the large impact of EâCTCL and the major consequences on the physical functioning as well as on the emotional/psychological and social wellâbeing. Mogamulizumab appears to have a positive effect on symptoms